• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of biosimilar investigational new drug applications (INDs) received in the month

Dictionary: Biosimilar investigational new drug application refers to an investigation that FDA determines is intended to support a biosimilar biological product application for a product.

Information is current as of March 31, 2014.

Fiscal Year - 2014

Skip graphic and jump to text data

TimeTargetNumber
Oct 2013N/A1
Nov 2013N/A2
Dec 2013N/A2
Jan 2014N/A0
Feb 2014N/A0
Mar 2014N/A0
Apr 2014N/ATBD
May 2014N/ATBD
Jun 2014N/ATBD
Jul 2014N/ATBD
Aug 2014N/ATBD
Sep 2014N/ATBD

FY 2014 YTD: 5

Footnotes

  • CDER began collecting data for this measure in January 2013.

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.